Lower Respiratory Tract Infection

Respiratory
1
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Ansun BioPharma
Ansun BioPharmaCA - San Diego
1 program
1
DAS181Phase 31 trial
Active Trials
NCT03808922Recruiting274Est. Aug 2025
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
AzithromycinN/A1 trial
Non-influenza Etiologies of Acute Respiratory Illness in Southeast AsiaN/A1 trial
Active Trials
NCT03341273TerminatedEst. Aug 2020
NCT01048073CompletedEst. Dec 2010
Abbott
AbbottABBOTT PARK, IL
1 program
Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody TherapyN/A1 trial
Active Trials
NCT00420966Completed25,003Est. Jun 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Ansun BioPharmaDAS181
Allergy TherapeuticsAzithromycin
Allergy TherapeuticsNon-influenza Etiologies of Acute Respiratory Illness in Southeast Asia
AbbottUtilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy

Clinical Trials (4)

Total enrollment: 25,277 patients across 4 trials

NCT03808922Ansun BioPharmaDAS181

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Start: May 2019Est. completion: Aug 2025274 patients
Phase 3Recruiting
NCT03341273Allergy TherapeuticsAzithromycin

Placebo-Controlled Trial of Antibiotic Therapy in Adults With Suspect Lower Respiratory Tract Infection (LRTI) and a Procalcitonin Level

Start: Dec 2017Est. completion: Aug 2020
N/ATerminated
NCT01048073Allergy TherapeuticsNon-influenza Etiologies of Acute Respiratory Illness in Southeast Asia

Non-influenza Etiologies of Acute Respiratory Illness in Southeast Asia

Start: May 2010Est. completion: Dec 2010
N/ACompleted
NCT00420966AbbottUtilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy

Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy

Start: Oct 2005Est. completion: Jun 201725,003 patients
N/ACompleted

Related Jobs in Respiratory

Regional Gene Therapy Consultant - Upper Midwest (IL/WI/MN)

Krystal Biotech
1h ago
$185K - $215K/yr

Regional Gene Therapy Consultant - Southwest (CO/AZ/NM/UT)

Krystal Biotech
1h ago
$185K - $215K/yr

Ausbildung zum Pharmakanten (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Marketing Intern – Vertex Iberia (Spain)

Vertex Pharmaceuticals
Madrid, Spain
Yesterday

Sales Rep Neurology Region Leipzig, Halle, Gera, Jena, Weimar DE_G2M110105 - befristet bis 31.03.2027 (all genders)

Sanofi
Berlin
Yesterday

Laboratory Assistant (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
2d ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 25,277 patients
3 companies competing in this space

Related Indications

Asthma(378)Pulmonary Disease, Chronic Obstructive(263)Chronic Obstructive Pulmonary Disease(123)Idiopathic Pulmonary Fibrosis(90)COPD(74)Chronic Obstructive Pulmonary Disease (COPD)(38)Pulmonary Embolism(27)Respiratory Syncytial Virus Infections(26)Severe Asthma(21)Lung Diseases, Interstitial(19)